Clinical bottom line
Selective Bruton tyrosine kinase (BTK) inhibitors represent an important advancement in the treatment of relapsed/refractory mantle cell lymphoma (MCL), offering improved efficacy and tolerability compared to earlier covalent BTK inhibitors. Emerging agents such as acalabrutinib and zanubrutinib have demonstrated meaningful progression-free survival benefits with potentially fewer off-target effects, making them valuable options for patients who have progressed after first-line therapy. However, long-term comparative data remain limited, and resistance mechanisms are an ongoing challenge. Clinicians should consider patient comorbidities, prior therapies, and toxicity profiles when selecting BTK inhibitors, while awaiting further evidence to guide sequencing and combination strategies.
What the evidence shows
Mantle cell lymphoma is an aggressive B-cell non-Hodgkin lymphoma subtype with historically poor outcomes in the relapsed/refractory setting. BTK inhibitors have transformed management by targeting B-cell receptor signaling, a critical pathway in MCL pathogenesis.
Ibrutinib, the first-in-class covalent BTK inhibitor, showed significant activity in relapsed/refractory MCL with overall response rates (ORR) around 65-70% and median progression-free survival (PFS) of approximately 13-15 months in pivotal phase II and III trials (Wang et al., 2013; Wang et al., 2016). However, ibrutinib’s off-target inhibition of kinases such as EGFR and TEC contributes to adverse events including atrial fibrillation, bleeding, and hypertension, leading to treatment discontinuation in some patients.
Second-generation selective BTK inhibitors acalabrutinib and zanubrutinib have been developed to improve selectivity and reduce toxicity. The phase II ACE-LY-004 trial demonstrated acalabrutinib monotherapy achieved an ORR of 81% and median PFS of 20 months in relapsed/refractory MCL, with a more favorable safety profile compared to historical ibrutinib data (Wang et al., 2020). Similarly, zanubrutinib showed an ORR of 84% and median PFS of 22 months in a phase II study (Tam et al., 2020).
The phase III ALPINE trial directly compared zanubrutinib to ibrutinib in relapsed/refractory MCL, reporting superior ORR (84% vs 75%) and lower rates of atrial fibrillation and bleeding with zanubrutinib (Tam et al., 2023). These results suggest improved efficacy and tolerability with newer selective BTK inhibitors.
Despite these advances, resistance to BTK inhibitors remains a clinical challenge. Mechanisms include BTK C481S mutations and activation of alternative pathways, underscoring the need for combination strategies and novel agents (Wang et al., 2021).
Current NCCN guidelines (version 4.2024) endorse acalabrutinib, zanubrutinib, and ibrutinib as preferred options for relapsed/refractory MCL, with selection individualized based on patient factors and toxicity considerations.
Caveats and uncertainty
Most data on selective BTK inhibitors derive from single-arm phase II trials or indirect comparisons, limiting definitive conclusions on superiority. The ALPINE trial provides the strongest head-to-head evidence but longer follow-up is needed to confirm durability of response and overall survival benefit.
Patient populations in trials often exclude those with significant cardiac comorbidities or prior BTK inhibitor exposure, restricting generalizability. Real-world evidence is emerging but limited.
Resistance mechanisms and optimal sequencing of BTK inhibitors remain incompletely understood. The role of BTK inhibitors in combination with other targeted agents or immunotherapies is under active investigation but not yet standard.
Toxicity profiles, while improved, still require vigilance for bleeding, infections, and rare cardiac events. Dose modifications and supportive care are important to maintain treatment adherence.
How this may change practice
Selective BTK inhibitors acalabrutinib and zanubrutinib provide clinicians with effective, generally better-tolerated options for relapsed/refractory MCL, potentially improving quality of life and treatment adherence compared to ibrutinib.
These agents may be preferred in patients at higher risk for cardiac or bleeding complications. The availability of multiple BTK inhibitors allows tailoring therapy based on individual patient comorbidities and prior treatment history.
Ongoing trials and emerging real-world data will clarify optimal sequencing and combination approaches, potentially expanding the role of BTK inhibitors earlier in the disease course or in combination regimens.
Clinicians should monitor for resistance and adverse events, and consider referral for clinical trials exploring novel agents and strategies to overcome BTK inhibitor resistance.